Conference Paper: Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients

File Download

No File Attached
The HKU Scholars Hub has contact details for these author(s).

Links for fulltext
(May Require Subscription)

Publisher Website: 10.1007/s12072-010-9241-z

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Surgery: Conference papers

Title	Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients
Authors	Cheung, TT Poon, RTP Lo, CM Fan, ST
Keywords	Medical sciences Endocrinology
Issue Date	2011
Publisher	Springer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation	The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13 [How to Cite?] DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
Abstract	High intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient’s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.
Description	pp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
ISSN	1936-0533 2011 Impact Factor: 2.645 2011 SCImago Journal Rankings: 0.244
DOI	http://dx.doi.org/10.1007/s12072-010-9241-z

DC Field	Value
dc.contributor.author	Cheung, TT
dc.contributor.author	Poon, RTP
dc.contributor.author	Lo, CM
dc.contributor.author	Fan, ST
dc.date.accessioned	2011-07-27T02:02:45Z
dc.date.available	2011-07-27T02:02:45Z
dc.date.issued	2011
dc.description.abstract	High intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient’s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.
dc.description	pp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011
dc.description.other	The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13
dc.identifier.citation	The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13 [How to Cite?] DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
dc.identifier.doi	http://dx.doi.org/10.1007/s12072-010-9241-z
dc.identifier.epage	454
dc.identifier.hkuros	188342
dc.identifier.issn	1936-0533 2011 Impact Factor: 2.645 2011 SCImago Journal Rankings: 0.244
dc.identifier.issue	1
dc.identifier.spage	453
dc.identifier.uri	http://hdl.handle.net/10722/136096
dc.identifier.volume	5
dc.language	eng
dc.publisher	Springer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
dc.publisher.place	United States
dc.relation.ispartof	Hepatology International
dc.rights	The original publication is available at www.springerlink.com
dc.subject	Medical sciences
dc.subject	Endocrinology
dc.title	Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Cheung, TT</contributor.author><contributor.author>Poon, RTP</contributor.author><contributor.author>Lo, CM</contributor.author><contributor.author>Fan, ST</contributor.author><date.accessioned>2011-07-27T02:02:45Z</date.accessioned><date.available>2011-07-27T02:02:45Z</date.available><date.issued>2011</date.issued><identifier.citation>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13</identifier.citation><identifier.issn>1936-0533</identifier.issn><identifier.uri>http://hdl.handle.net/10722/136096</identifier.uri><description>pp. 3-558 of this journal issue contain Abstracts of the 21st APASL Conference 2011</description><description.abstract>High intensive focused ultrasound ablation (HIFU) is a novo noninvasive ablation methods for hepatocellular carcinoma (HCC). Emerging evidence has shown that it is effective in the treatment of HCC particularly in patient with poor liver function. Unlike partial hepatectomy or RFA for HCC on patients with cirrhosis, there are no data on the safety limit of HIFU. However, information is vital for the selection of appropriate patients for the procedure. In this study, we analyzed the results of HIFU on HCC patients and determined the lower limit of liver function and other patient&#8217;s factors with which HCC patients can tolerate HIFU. METHOD: Preoperative variables of consecutive 100 patients who underwent HIFU for HCC were analyzed to identify the risk factors in HIFU intolerance in terms of morbidity associated with stress-induced complications. RESULTS: 15 patients were in Child Pugh grade B liver cirrhosis and 1 patient was in Pugh Child C liver cirrhosis. 15 patients presented with ascites before treatment. Thirteen (13%) patients developed intolerance to HIFU. Postoperative morbidity was mainly due to skin and subcutaneous injury (n = 9), five patients developed first degree skin burn, one patient developed second degree skin burn and three patients developed third degree skin burn. Two patients developed pneumothorax, one patient developed hyperbilirubinemia and six patients developed other complications. Univariated analysis only showed that age (p = 0.022) is the single independent factor that predict the development of intolerance. CONCLUSIONS: HIFU is generally well tolerated inpatients with cirrhosis. This is a safe method for patients even when TACE is considered risky as a treatment modality. This ablative treatment modality can be used in selected patients with Pugh Child C liver cirrhosis.</description.abstract><language>eng</language><publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0</publisher><relation.ispartof>Hepatology International</relation.ispartof><rights>The original publication is available at www.springerlink.com</rights><subject>Medical sciences</subject><subject>Endocrinology</subject><title>Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients</title><type>Conference_Paper</type><identifier.doi>10.1007/s12072-010-9241-z</identifier.doi><identifier.hkuros>188342</identifier.hkuros><identifier.volume>5</identifier.volume><identifier.issue>1</identifier.issue><identifier.spage>453</identifier.spage><identifier.epage>454</identifier.epage><publisher.place>United States</publisher.place><description.other>The 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 453-454, abstract PP33-13</description.other></item>

Conference Paper: Safety and tolerance of high intensive focused ultrasound ablation for hepatocellular carcinoma in 100 consecutive patients

The HKU Scholars Hub has contact details for these author(s).